AbbVie's ALTITUDE trial of RGX-314 gene therapy for diabetic retinopathy marked completed
The Phase 2 ALTITUDE study testing suprachoroidal RGX-314 in diabetic retinopathy with and without macular edema shows a completed status with a final record update posted November 16, 2026.
AbbVie's registry update this week centers on one gene therapy trial for diabetic eye disease.
- "ALTITUDE" (NCT04567550), a Phase 2 trial of ABBV-RGX-314 gene therapy given by suprachoroidal injection, is listed as completed, with primary and study completion dated 2026-06-18. The study enrolled 139 participants1. It tested about 100 participants with diabetic retinopathy without center-involved diabetic macular edema in Part 1, and about 30 participants with center-involved diabetic macular edema in Part 21, with sponsorship from AbbVie and collaboration from REGENXBIO Inc.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.